[ad_1]
Prof. Dr. Uğur Şahin and Dr. Pfizer CEO Albert Bourla, which is the most authorized name of the company, announced when the first application of the vaccine developed by the BioNTech company founded by Özlem Türeci with the pharmaceutical company could be made American Pfizer.
Vaccination is expected to begin on December 13 at the earliest, after US pharmaceutical giant Pfizer and Biontech approached the US Food and Drug Administration (FDA) for approval of the vaccine developed against Covid-19 and announced to be effective. to 95%. .
“Warp Speed Operation” President Moncef Slaoui, initiated by the Trump administration for Covid-19 vaccine studies, told CNN television: “We plan to send the vaccine to vaccination centers within 24 hours of approval. of the vaccine “. She said.
Slaoui said he expected the approval to be finalized on 11 or 12 December.
Vaccination procedures should begin with healthcare professionals first.
CEO ALBERT BOURLA ANNOUNCED THE STORY IN ONE DAY
Albert Bourla, CEO of US pharmaceutical giant Pfizer, said in the video released on Friday: “Today is a historic day, today is a historic day for science and for all of us.”
“It’s been 248 days from the day we announced our cooperation plans with BioNTech, until the application we submitted today to the US Food and Drug Administration,” Bourla said in his message.
Albert Bourla continued: “From conception to licensing applications, we have worked at an extraordinary pace in our clinical development program, while maintaining our focus on safety.”
Pfizer was the first company in the United States to apply for a license for the corona virus vaccine. As stated today by Pfizer and BioNTech; The vaccine candidate, known as “BNT 162b2”, could potentially be used in high-risk population groups in the United States in mid-December.
MINISTER KOCA: 1 MILLION DOSE WILL ARRIVE IN THE FIRST PHASE
Health Minister Fahrettin’s husband obtained a license for the vaccine virus in December and Turkey announced that 1 million doses will be provided.
Fahrettin Koca, Prof. Dr. Uğur Şahin and Dr. Özlem Türeci added that the vaccine developed by the couple’s company BioNTech could increase the supply quantity to 25 million doses in 2021.
The application to the American Drug Administration is based on the results of the third phase of the vaccine clinical trials. Vaccine testing began in the United States on July 27, and more than 43,000 people were tested in the process.
SOURCE: ANADOLU AGENCY
Source link
